EUVIMEDEUVIMED entdecken
Crossref

Clinical toxicity of nitazene detections in two Australian emergency department toxicosurveillance systems

Katherine Z Isoardi iD, Sam Alfred iD, Courtney Weber iD, Keith Harris iD, Jessamine Soderstrom iD, Rebekka Syrjanen iD, Amanda Thompson, Jennifer Schumann iD, Peter Stockham iD, Paul Sakrajda iD, Daniel Fatovich iD, Shaun L Greene iD und 1 weitere

Drug and Alcohol Review · 2026

DOI: 10.1111/dar.13998 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug and Alcohol Review, 2026. Verfasst von Katherine Z Isoardi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Toxicology Unit, Princess Alexandra Hospital, Brisbane, Australia. Hauptthemen laut MEDLINE: Emergency Service, Hospital, Analgesics, Opioid. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Nitazenes are a group of potent synthetic opioids that have had increasing prominence as novel psychoactive drugs in the last 5 years. We describe emergency department nitazene‐related presentations.

Methods

This is a prospective series of patients with analytically confirmed nitazene presentations identified by the Emerging Drugs Network of Australia and Emerging Drugs Network of Australia Victoria. Both studies' databases were searched between July 2020 and February 2024 with clinical data and blood nitazene concentrations abstracted.

Results

There were 32 presentations, 23 (72%) males, with a median age of 31 years (range 18–63 years). Only five (16%) intentionally ingested a nitazene, with most (12, 38%) believing they had taken alternative opioids. Co‐exposures occurred in 31 (97%), mostly metamfetamine. Naloxone was administered in 23 (72%) presentations, with a median total dose of intravenous naloxone within 1 h post hospital presentation of 400 μg (interquartile range [IQR] 160–450 μg). Four (13%) received a naloxone infusion. Thirteen (41%) were admitted to the intensive care unit. The median length of stay was 17 h (IQR 7–39 h). Protonitazene was the commonest nitazene detected in 23 (72%) presentations with a median concentration of 2.0 μg/L (range 0.7–15 μg/L). The lowest concentration of protonitazene in a patient that received naloxone was 0.7 μg/L. Discussion and Conclusions Most patients were unaware they were using nitazenes. Given their potency, this has important implications for harm, particularly in those not intentionally using opioids. Nitazene exposure was mostly unintentional. Naloxone use was common and standard dosing regimens appeared effective in most cases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Emergency Service, HospitalAnalgesics, OpioidHumansAdultMaleAdolescentYoung AdultFemaleMiddle AgedNaloxoneProspective StudiesAustraliaNarcotic AntagonistsVictoriaMethaneNitroparaffins

Stichwörter der Autor:innen

naloxonenitazenenovel psychoactive substanceopioidpoisoning

Substanzen

NaloxoneNarcotic AntagonistsAnalgesics, OpioidnitromethaneMethaneNitroparaffins

Autor:innen und Institutionen

  • Clinical Toxicology Unit, Princess Alexandra Hospital, Brisbane, Australia.
  • Faculty of Medicine, University of Queensland, Brisbane, Australia.
  • Royal Adelaide Hospital, Adelaide, Australia.
  • Faculty of Medicine, University of Adelaide, Adelaide, Australia.
  • Centre for Clinical Research in Emergency Medicine, Harry Perkins Institute of Medical Research, Perth, Australia.
  • School of Population and Global Health, University of Western Australia, Perth, Australia.

ORCID-Profile: Katherine Z Isoardi, Sam Alfred, Courtney Weber, Keith Harris, Jessamine Soderstrom, Rebekka Syrjanen, Jennifer Schumann, Peter Stockham, Paul Sakrajda, Daniel Fatovich, Shaun L Greene

Förderung

  • National Health and Medical Research Council

Zitieren

APA

Isoardi, K. Z., Alfred, S., Weber, C., Harris, K., Soderstrom, J., Syrjanen, R., Thompson, A., Schumann, J., Stockham, P., Sakrajda, P., Fatovich, D., Greene, S. L., & EDNA and EDNAV Investigators (2026). Clinical toxicity of nitazene detections in two Australian emergency department toxicosurveillance systems. Drug and Alcohol Review. https://doi.org/10.1111/dar.13998

Vancouver

Isoardi KZ, Alfred S, Weber C, Harris K, Soderstrom J, Syrjanen R, et al. Clinical toxicity of nitazene detections in two Australian emergency department toxicosurveillance systems. Drug and Alcohol Review. 2026. doi:10.1111/dar.13998

BibTeX
@article{Isoardi2026,
  author = {Isoardi, Katherine Z and Alfred, Sam and Weber, Courtney and Harris, Keith and Soderstrom, Jessamine and Syrjanen, Rebekka and Thompson, Amanda and Schumann, Jennifer and Stockham, Peter and Sakrajda, Paul and Fatovich, Daniel and Greene, Shaun L and EDNA and EDNAV Investigators, EDNA and EDNAV Investigators},
  title = {Clinical toxicity of nitazene detections in two Australian emergency department toxicosurveillance systems},
  journal = {Drug and Alcohol Review},
  year = {2026},
  doi = {10.1111/dar.13998}
}
Kostenlos starten →